rxdx-105
Small moleculeexperimental
Clinical trial activity
3 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
2
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 1, 2013 (NCT01877811)
Timeline
2010s
- Jan 1, 2013
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- rxdx-105
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT03784378 | Phase 1 | Dec 14, 2018 | Memorial Sloan-Kettering Cancer Center |
| NCT03052569 | N/A | Feb 10, 2017 | Ignyta, Inc. |
| NCT01877811 | Phase 1 | Jun 1, 2013 | Ignyta, Inc. |
Showing 3 of 3 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Ignyta, Inc. | For profit | 2 | 2 | 2 | 2013 |
| Memorial Sloan-Kettering Cancer Center | Academic/Hospital | 1 | 1 | 1 | 2018 |
2 organizations
Page 1 / 1